Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

By sjmartinez • March 27, 2025

Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03666-y. Epub ahead of print. Erratum for: Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. PMID: 40140623.

Tags: General Internal Medicine, Publications, Resident

Forearm BMD predicts fracture independently of FRAX

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Cauley JA, Crandall CJ, Huisman M, Khosla S, Kwok T, Mellström D, Orwoll ES, van Schoor NM,[...]

Breaking Barriers to Transplantation: Desensitization with Daratumumab in Peripartum Cardiomyopathy

Okwuosa I, Kumar A, Choi SM, Kamath M, Vellanki S. Breaking Barriers to Transplantation: Desensitization with Daratumumab in Peripartum Cardiomyopathy. Can J Cardiol. 2026 Apr[...]

Mechanical augmentation for vertebral compression fractures: A scoping review

Sen H, Ni AY, Cooper AN, Limerick G, Cardenas-Rojas A, Mahendram S, Osman SK, Radlicz C, Tram J, Teramoto M, Kanjanapanang N, McCormick ZL, Conger[...]